Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)
NICE is unable to make a recommendation on bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults because Merck Sharp&Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.9b01198
AbstractIn acute gastroenteritis (AGE), identification of the infectious agent is important for patient management. Since symptoms do not reliably identify the agent, microbiological diagnostics are important. Conventional methods lack sensitivity and often take days. Multiplex PCR panels offer fast and sensitive alternatives. Our aim was to assess the performance of the new QIAstat Gastrointestinal Panel (GIP) detecting 24 different gastroenteric pathogens from stool in Cary-Blair transport medium (Adenovirus F 40/41, Astrovirus, Norovirus GI/GII, Rotavirus A, Sapovirus,Campylobacter spp.,Clostridium difficile,Plesiomonas...
Conclusions: Recurrent CA-CDI in children in our population is less common than previously reported. This study supports first-line treatment with the standard, short course metronidazole in most cases of primary CA-CDI.
ConclusionUtilising SNA and GIS analysis in conjunction with one another provided a data ‐rich environment in which the risk inherent in intra‐hospital transfer networks was quantified, visualised and interpreted for potential interventions.
This study revealed that disruption of the lone lrp homolog in C. difficile decelerated growth under nutrient-limiting conditions, increased TcdA and TcdB production. Lrp was also found to negatively regulate sporulation while positively regulate swimming motility in strain R20291, but not in strain 630. The C. difficile Lrp appeared to function through transcriptional repression or activation. In addition, the lrp mutant was relatively virulent in a mouse model of infection. The results of this study collectively demonstrated that Lrp has broad regulatory function in C. difficile toxin expression, sporulation, motility, and pathogenesis.
Authors: Bruno G, Gagliardi A, Oliva A, Trancassini M, Macone A, Cicerone C, D'Abramo A, Iebba V, Auria S, Bonfiglio G, Zingaropoli MA, D'Ettorre G, Badiali D, Vullo V, Corazziari ES, Schippa S Abstract This short communication reports the preliminary results of Fecal Microbial Transplantation (FMT) impact on microbiota, microbial translocation (MT), and immune activation in four recurrent Clostridium difficile infection (R-CDI) patients. After FMT a restore of gut microbiota composition with a significant increase of fecal acetyl-putrescine and spermidine and fecal acetate and butyrate, a decrease of immune activa...
ConclusionOur findings suggest that curcumin has potential as an anticlostridial agent. More work is needed to further investigate the efficacy of curcumin as a standalone drug or as a supplement of current drugs of choice, as it has no antagonistic activities but might overcome their drawbacks.
ConclusionsIn our cohort, obesity was associated with low risk of CDP among hospitalized patients with pouchitis. This finding warrants further validation in prospective studies.
Fecal microbiota transplantation (FMT) is an effective tool for treating Clostridium difficile infection in the setting of dysbiosis of the intestinal microbiome. FMT for other forms of human disorders linked to dysbiosis have been less effective. The fecal microbiota contains a high density of virus-like particles (VLP), up to 90% of which are bacteriophages, thought to have a role in regulating gut bacterial populations. We hypothesized that transplantation of the phage-containing fecal VLP fraction may reduce bacterial density in the dysbiotic setting of small intestinal bacterial overgrowth (SIBO). In an experiment usi...
The tests often are positive in people without symptoms, particularly older patients. The result: overtreatment with antibiotics.